Home Stock

Stock Research: MedinCell

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

MedinCell

PAR:MEDCL FR0004065605
19
  • Value
    26
  • Growth
    61
  • Safety
    Safety
    6
  • Combined
    17
  • Sentiment
    59
  • 360° View
    360° View
    19
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The company develops therapeutic solutions with worldwide access, collaborating with pharmaceutical corporations, physicians, biotechnology firms, academics, and foundations. Their main businesses include developing long-acting injectable medicines for various therapeutic areas such as schizophrenia, post-surgical pain and inflammation, contraception, and depression. In the last fiscal year, the company had a market cap of $622 million and revenue of $27 million.

more

ANALYSIS: With an Obermatt 360° View of 19 (better than 19% compared with alternatives), overall professional sentiment and financial characteristics for the stock MedinCell are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half of the metrics below and half above average for MedinCell. The consolidated Growth Rank has a good rank of 61, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. This means that growth is higher than for 61% of competitors in the same industry. The consolidated Sentiment Rank also has a good rank of 59, which means that professional investors are more optimistic about the stock than for 59% of alternative investment opportunities. But the consolidated Value Rank has a less desirable rank of 26, which means that the share price of MedinCell is on the higher side compared with typical size in indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 74% of alternative stocks in the same industry. Finally, the consolidated Safety Rank has a riskier rank of 6, which means that the company has a financing structure that is riskier than those of 94% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. ...read more

more
Strongest Rank Price vs. Book (P/B)
Weakest Rank Analyst Opinions
Country France
Industry Pharmaceuticals
Size Small
Website medincell.com
Index
CAC All
SBF 120
MedinCell stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
26 22 41 56
Growth
61 92 87 5
Safety
Safety
6 4 1 8
Sentiment
59 27 20 20
360° View
360° View
19 23 8 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
100 87 93 87
Opinions Change
50 28 17 50
Pro Holdings
n/a 38 47 8
Market Pulse
15 1 3 11
Sentiment
59 27 20 20
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
26 22 41 56
Growth
61 92 87 5
Safety Safety
6 4 1 8
Combined
17 26 26 4
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
15 5 16 34
Price vs. Earnings (P/E)
100 1 100 68
Price vs. Book (P/B)
1 100 100 100
Dividend Yield
1 1 1 1
Value
26 22 41 56
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
98 98 100 28
Profit Growth
26 51 67 28
Capital Growth
25 83 31 16
Stock Returns
74 88 60 14
Growth
61 92 87 5
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
5 1 1 3
Refinancing
33 21 1 52
Liquidity
26 19 19 17
Safety Safety
6 4 1 8

Similar Stocks

Discover high‑ranked alternatives to MedinCell and broaden your portfolio horizons.

ENGIE

PAR:ENGI
Country: France
Industry: Multi-Utilities
Size: Large
Full Stock Analysis

Manitou BF

PAR:MTU
Country: France
Industry: Heavy Machinery
Size: Medium
Full Stock Analysis

Rubis

PAR:RUI
Country: France
Industry: Gas Utilities
Size: Large
Full Stock Analysis

Faes Farma

MCE:FAE
Country: Spain
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a classic, high-risk growth play: high growth and positive sentiment outweigh low Value Rank (expensive) and risky financing. This is for aggressive growth investors who are comfortable with the high price and risk, believing the growth story justifies the expense.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews